Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib

Table 1 List of mutations identified in next-generation sequencing with potential treatments, adapted from the patient’s FoundationOne^® report

Mutation	Description	Potential treatments^a
ERBB3	R135C	Lapatinib, trastuzumab, afatinib, pertuzumab, ado-trastuzumab emtansine
NF2	Q400	Everolimus, temsirolimus, FAK inhibitors, lapatinib, trametinib
CDKN2A	P16INK4a D84Y and p14ARF 98L	Abemaciclib, ribociclib, palbociclib
CARD11	R888C	NF-kB inhibitors
FAT1	C3738fs*12
LRP1B	G4199E
RUNX1T1	R394W
TERT promoter	− 139_− 138 CC > TT
TP53	R196*, R282W	AZD1775, APR-246, SGT-53, CHK1 inhibitor with irinotecan, kevetrin

In the FAT1 and TP53 mutations, the “*” denotes a mutation in a stop codon. In the FAT1 mutation, “fs” denotes a frameshift mutation. In the TERT promoter mutation, “−” denotes the affected nucleotide, “_” denotes the range of affected residues, and “>” denotes a substitution mutation
^a Not all listed treatments are FDA-approved and some are drawn from data found in preclinical and/or early clinical studies

ISSN: 2162-3619